CN110869382A - 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途 - Google Patents

甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途 Download PDF

Info

Publication number
CN110869382A
CN110869382A CN201880047097.8A CN201880047097A CN110869382A CN 110869382 A CN110869382 A CN 110869382A CN 201880047097 A CN201880047097 A CN 201880047097A CN 110869382 A CN110869382 A CN 110869382A
Authority
CN
China
Prior art keywords
compound
formula
crystal
degrees
diffraction peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880047097.8A
Other languages
English (en)
Other versions
CN110869382B (zh
Inventor
李小林
肖华玲
李鹏
贺海鹰
李卫东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN110869382A publication Critical patent/CN110869382A/zh
Application granted granted Critical
Publication of CN110869382B publication Critical patent/CN110869382B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

甾体类衍生物FXR激动剂（式I）的结晶或无定型物、及其制备方法，包含该结晶或无定型物的结晶组合物、药物组合物，以及它们在制备治疗或预防FXR相关各种病症的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201880047097.8A 2017-07-26 2018-07-26 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途 Active CN110869382B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710619423 2017-07-26
CN2017106194235 2017-07-26
PCT/CN2018/097161 WO2019020068A1 (zh) 2017-07-26 2018-07-26 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN110869382A true CN110869382A (zh) 2020-03-06
CN110869382B CN110869382B (zh) 2021-06-25

Family

ID=65039986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880047097.8A Active CN110869382B (zh) 2017-07-26 2018-07-26 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途

Country Status (7)

Country Link
US (1) US11059853B2 (zh)
EP (1) EP3660031A4 (zh)
JP (1) JP7244487B2 (zh)
CN (1) CN110869382B (zh)
AU (1) AU2018305612B2 (zh)
CA (1) CA3070631A1 (zh)
WO (1) WO2019020068A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7308811B2 (ja) * 2017-07-26 2023-07-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ステロイド系誘導体ｆｘｒアゴニストの製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086169A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN105801653A (zh) * 2014-12-30 2016-07-27 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN109071593A (zh) * 2016-01-28 2018-12-21 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356887A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
US20180148470A1 (en) * 2015-04-28 2018-05-31 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
JP7308811B2 (ja) * 2017-07-26 2023-07-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ステロイド系誘導体ｆｘｒアゴニストの製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086169A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN105801653A (zh) * 2014-12-30 2016-07-27 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN109071593A (zh) * 2016-01-28 2018-12-21 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YUSUKE IGUCHI等: "Structure–activity relationship of bile alcohols as human farnesoid X receptor agonist", 《STEROIDS》 *
年四昀 等: "法尼醇X受体激动剂的研究进展", 《中国药物化学杂志》 *

Also Published As

Publication number Publication date
EP3660031A1 (en) 2020-06-03
WO2019020068A8 (zh) 2019-05-02
CN110869382B (zh) 2021-06-25
RU2020106148A (ru) 2021-08-10
EP3660031A4 (en) 2021-03-31
AU2018305612A1 (en) 2020-02-06
JP7244487B2 (ja) 2023-03-22
WO2019020068A1 (zh) 2019-01-31
CA3070631A1 (en) 2019-01-31
US11059853B2 (en) 2021-07-13
US20200231621A1 (en) 2020-07-23
AU2018305612B2 (en) 2022-04-14
JP2020528067A (ja) 2020-09-17

Similar Documents

Publication Publication Date Title
ES2811478T3 (es) Nueva sal de adición de ácido de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina
US10301287B2 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US11634388B2 (en) Crystal form of lenvatinib mesylate and preparation method therefor
US8148353B2 (en) Polymorphs of fluticasone furoate and process for preparation thereof
RU2648990C1 (ru) Кристаллы лобаплатина, способы получения и применения в фармацевтике
CN110869382B (zh) 甾体类衍生物fxr激动剂的结晶或无定型物、其制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP2019529481A (ja) 胆汁酸誘導体の結晶形態
CN113439083A (zh) 二芳基硫代乙内酰脲化合物结晶
US8138343B2 (en) Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
RU2753335C2 (ru) Кристалл ингибитора DPP-IV длительного действия и его соли
RU2800751C2 (ru) Кристаллическая или аморфная форма агонистов fxr, представляющих собой производные стероидов, способ их получения и их применение
US20230123104A1 (en) Crystal of tricyclic compound acting on crbn protein and preparation method therefor
CN111574441B (zh) 一种尼可地尔与水杨酸的共晶及其制备方法和应用
CN111362873B (zh) 一种加替沙星代谢物的合成方法
WO2021000687A1 (zh) Pac-1晶型的制备方法
CN110869381B (zh) 甾体类衍生物fxr激动剂的制备方法
RU2810214C2 (ru) Кристалл диарилтиогидантоинового соединения
CN115109083B (zh) Pyridostatin类化合物及其制备方法、应用、药物组合物
JP7350854B2 (ja) Ｆｘｒ作動薬の固体形態、結晶形態、結晶体ａ、その調製方法および応用
RU2804320C2 (ru) Твердая форма, кристаллическая форма и кристаллическая форма а агониста fxr, и способ их получения, и их применение
CN117164651A (zh) D-生物素标记的藏红花素探针及其合成方法
CN105330715B (zh) 一种牛磺熊去氧胆酸的制备方法
CN116554171A (zh) 一种brd4抑制剂类化合物的新晶型、用途及其制备方法
CN117843621A (zh) 一种新型哒嗪类化合物及其药物组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019731

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant